

After having backed Gyrus Capital in its first transaction, Headway Capital's advised fund HIP IV SCSp is pleased to have supported Gyrus Capital again in its second transaction, as described in the [following press release](#):

January 30, 2020

Gyrus Capital completes buy-out of Essential Pharma



Essential Pharma buy-out

Management of Essential Pharma, supported by Gyrus Capital, have acquired 100% of the shares of the Essential Pharma Group from the founder family owners.

Terms of the transaction were not disclosed but operations and management of the Essential Pharma group will remain unchanged. Essential Pharma is based in Egham, Surrey, and is a specialty generic pharma business focussed on CNS and other niche pharmaceutical products. Essential addresses the problem of drug shortages by ensuring the continued supply of low volume and legacy drugs with high clinical importance which are at risk of discontinuation and stockouts.

With additional funding from Gyrus Capital, Essential plans continue to grow the business through further product acquisitions in Europe, and potential add-ons.

Gyrus Capital is an investment firm based in Geneva, Switzerland. The firm makes investments in long term sustainable growth sectors, specifically healthcare and sustainability. Essential Pharma represents the firm's second investment after the carve out of DuPont Sustainable Solutions was completed in August 2019.

ADVISORS:

Gyrus Capital: Guy Semmens; Dr Robert Watson; Simon Cottle (Operating and Advisory Partnership). www.gyruscapital.com

Financial advisors to Gyrus: Deloitte

Legal advisors to Gyrus: Clifford Chance

Debt providers: Hayfin Capital Management